Beyond Boundaries: The Transformative Potential of Spironolactone in Female Pattern Hair Loss

Spironolactone, a potassium-sparing diuretic with antiandrogenic properties, has shown promise as an effective systemic therapy for Female Pattern Hair Loss (FPHL), a condition characterized by diffuse thinning over the crown. The drug works by inhibiting androgen receptors, suppressing 5-α reductase activity, reducing circulating androgens, and stabilizing the hair growth cycle. Clinical studies have reported improvements in hair density, reduced shedding, and disease stabilization, especially in women with hyperandrogenism. Spironolactone is generally well tolerated, cost-effective, and supports good long-term adherence with proper monitoring. However, hair loss often recurs after stopping treatment, suggesting the need for ongoing therapy. Future research should focus on larger trials to determine optimal dosing and long-term safety, and explore novel topical formulations and combination therapies to enhance outcomes.